Bryan Johnson, a prominent figure in the tech industry, recently made headlines for his unconventional approach to reversing the effects of aging. The 47-year-old millionaire entrepreneur embarked on a journey to combat the signs of aging after experiencing a significant weight loss that left him with a gaunt appearance, particularly in his face.
Johnson’s anti-aging initiative, dubbed “Project Baby Face,” involved a procedure in which he received injections of donor fat into his face. However, the procedure took a severe turn when Johnson suffered a severe allergic reaction shortly after the injections. His face swelled rapidly, to the point where his vision was impaired. Despite the setback, Johnson remained undeterred and reassured his audience that the swelling had subsided after a week, and he was already planning his next attempt at the procedure.
Known for his involvement in the longevity movement, Johnson is the founder of the ‘Don’t Die’ program, which advocates for longer, healthier, and happier lives. In 2021, he garnered attention for launching Project Blueprint, a groundbreaking anti-aging endeavor that involved plasma transfusions from young anonymous donors. Johnson meticulously screened these donors to ensure they met specific criteria, such as having an ideal body mass index, being disease-free, and maintaining a healthy lifestyle.
Dedicated to his pursuit of eternal youth, Johnson reportedly allocates an annual budget of $2 million for anti-aging treatments. In a bold move in 2023, he engaged in a “multigenerational plasma exchange,” infusing himself with plasma from his 17-year-old son and having his 70-year-old father undergo a similar procedure. Johnson aims to maintain the vitality of a much younger individual, boasting of possessing the heart of a 37-year-old and the skin of a 28-year-old.
Johnson’s illustrious career in the tech industry includes founding Braintree in 2007, which later acquired Venmo for $26.2 million in 2012. Following Braintree’s success, Johnson sold the company to PayPal for $800 million in 2013, earning him over $300 million. In 2014, he established the OS Fund with $100 million to invest in emerging technologies. Subsequently, he founded Kernel in 2016, investing $100 million in the development of brain activity technology for conditions such as Alzheimer’s and strokes. By 2020, Kernel had secured $53 million in external investments.
With a background in International Studies and an MBA from the University of Chicago Booth School of Business, Bryan Johnson continues to be a trailblazer in the tech industry, pushing boundaries and challenging conventional norms in his quest for longevity and innovation.
